A5101760492- Acute Myeloid Leukemia Research
- Epigenetics and DNA Methylation
- Histone Deacetylase Inhibitors Research
- Acute Lymphoblastic Leukemia research
- Retinoids in leukemia and cellular processes
- Cancer-related gene regulation
- Cancer therapeutics and mechanisms
- Neutropenia and Cancer Infections
- Cell death mechanisms and regulation
- DNA Repair Mechanisms
- Protein Degradation and Inhibitors
- Lung Cancer Research Studies
- PARP inhibition in cancer therapy
- Cancer Genomics and Diagnostics
- Drug-Induced Ocular Toxicity
- Cancer-related Molecular Pathways
- Carcinogens and Genotoxicity Assessment
- CAR-T cell therapy research
- Hematopoietic Stem Cell Transplantation
- RNA modifications and cancer
- Trace Elements in Health
- Antioxidant Activity and Oxidative Stress
- Hepatocellular Carcinoma Treatment and Prognosis
- Bone and Joint Diseases
- Synthesis and Biological Evaluation
The University of Sydney
2025
National Cancer Institute
2020-2025
University of North Texas
2024
Sidney Kimmel Comprehensive Cancer Center
2006-2022
Johns Hopkins University
2005-2022
Yale University
1983-2022
Yale Cancer Center
2016-2022
University of Guelph
2016
Smilow Cancer Hospital
2015
Yale New Haven Hospital
2015
Abstract Optimal reexpression of most genes silenced through promoter methylation requires the sequential application DNA methyltransferase inhibitors followed by histone deacetylase in tumor cell cultures. Patients with myelodysplastic syndrome or acute myeloid leukemia (AML) were treated inhibitor 5-azacitidine (aza-CR) sodium phenylbutyrate. Major responses associated cytogenetic complete response developed patients receiving prolonged dosing schedules aza-CR. Bisulfite sequencing p15...
Incorporation of cytarabine into DNA activates checkpoint kinase 1 (Chk1), which stabilizes stalled replication forks, induces S-phase slowing, and diminishes cytotoxicity. The selective Chk1 inhibitor SCH 900776 abrogates cytarabine-induced arrest enhances cytotoxicity in acute leukemia cell lines leukemic blasts vitro. To extend these findings to the clinical setting, we have conducted a phase I study 900776.Twenty-four adults with relapsed refractory leukemias received timed sequential,...
PURPOSE To determine the feasibility of escalating hydrophilic topoisomerase I (topo I)-inhibitor topotecan (TPT) above myelosuppressive doses in adults with refractory or relapsed acute leukemias and to assess pharmacodynamic determinants TPT action. PATIENTS AND METHODS Seventeen patients received 33 courses as a 5-day infusion at ranging from 0.70 2.7 mg/m2/d. Pharmacologic studies were performed concentrations steady-state (Css) examine parameters patients' leukemic blasts ex vivo that...
PURPOSE Event-free survival following all-trans-retinoic acid (ATRA) -based therapy for acute promyelocytic leukemia (APL) averages 70% at 5 years. While arsenic trioxide (ATO) can induce remissions in 95% of relapsed patients, few studies have addressed the integration ATO into primary management APL. This study examines efficacy a single cycle ATO-based consolidation treatment regimen designed to decrease exposure other cytotoxic agents. PATIENTS AND METHODS After induction with ATRA and...
Abstract Purpose: Azanucleoside DNA methyltransferase (DNMT) inhibitors are currently approved by the U.S. Food and Drug Administration for treatment of myelodysplastic syndrome. The relative contributions DNMT inhibition other off-target effects to their clinical efficacy remain unclear. Data correlating methylation reversal response have been conflicting. Consequently, it is necessary investigate so-called impact on cell survival differentiation. Experimental Design: Flow cytometry was...
Nuclear localization of non-phosphorylated, active β-catenin is a measure Wnt pathway activation and associated with adverse outcome in patients acute myeloid leukemia (AML). While genetic alterations the are infrequent AML, inhibitors this silenced by promoter methylation other malignanices. Leukemia cell lines were examined for inhibitor total levels, had frequent upregulated Western blot immunofluorescence. One hundred sixty-nine AML samples genes. Diagnostic from 72 normal cytogenetics...
T-cell receptor (TCR) therapies are a promising modality for the treatment of cancers, with significant efforts being directed towards acute myeloid leukaemia (AML), particularly challenging disease. Chimeric antigen (CAR) T-cells targeting single surface antigens have shown remarkable efficacy B-cell lymphoblastic leukaemia, lymphomas and multiple myeloma. However, AML presents formidable obstacles to effectiveness CAR due widespread expression heterogenous immunophenotypes targets...
Aa total of 105 patients (age ≥18 years) with newly diagnosed low or intermediate risk acute promyelocytic leukaemia (APL) were treated a standard induction and consolidation regimen including arsenic trioxide (ATO). Sixty-eight who polymerase chain reaction (PCR) negative for PML-RARA post-consolidation randomized to either 1 year maintenance tretinoin, mercaptopurine methotrexate, observation. Enrollment in this non-inferiority trial was stopped prematurely due slow accrual. With median...